vs
OUTFRONT Media Inc.（OUT）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是OUTFRONT Media Inc.的1.5倍（$790.2M vs $513.3M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 18.9%，领先27.2%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs 4.1%），UNITED THERAPEUTICS Corp自由现金流更多（$173.3M vs $93.3M），过去两年OUTFRONT Media Inc.的营收复合增速更高（12.1% vs 8.0%）
OUTFRONT Media Inc.是一家美国广告企业，业务覆盖美国本土，由首席执行官Nick Brien领导美洲区业务，核心经营广告牌及公共交通展示广告两大业务板块，是户外广告领域的重要参与者。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
OUT vs UTHR — 直观对比
营收规模更大
UTHR
是对方的1.5倍
$513.3M
营收增速更快
UTHR
高出3.3%
4.1%
净利率更高
UTHR
高出27.2%
18.9%
自由现金流更多
UTHR
多$80.0M
$93.3M
两年增速更快
OUT
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $513.3M | $790.2M |
| 净利润 | $96.8M | $364.3M |
| 毛利率 | — | 86.9% |
| 营业利润率 | 26.0% | 45.1% |
| 净利率 | 18.9% | 46.1% |
| 营收同比 | 4.1% | 7.4% |
| 净利润同比 | 30.8% | 20.9% |
| 每股收益（稀释后） | $0.57 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OUTUTHR
| Q4 25 | $513.3M | $790.2M | ||
| Q3 25 | $467.5M | $799.5M | ||
| Q2 25 | $460.2M | $798.6M | ||
| Q1 25 | $390.7M | $794.4M | ||
| Q4 24 | $493.2M | $735.9M | ||
| Q3 24 | $451.9M | $748.9M | ||
| Q2 24 | $477.3M | $714.9M | ||
| Q1 24 | $408.5M | $677.7M |
净利润OUTUTHR
| Q4 25 | $96.8M | $364.3M | ||
| Q3 25 | $51.3M | $338.7M | ||
| Q2 25 | $19.5M | $309.5M | ||
| Q1 25 | $-20.6M | $322.2M | ||
| Q4 24 | $74.0M | $301.3M | ||
| Q3 24 | $34.6M | $309.1M | ||
| Q2 24 | $176.8M | $278.1M | ||
| Q1 24 | $-27.2M | $306.6M |
毛利率OUTUTHR
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
营业利润率OUTUTHR
| Q4 25 | 26.0% | 45.1% | ||
| Q3 25 | 19.2% | 48.6% | ||
| Q2 25 | 12.2% | 45.6% | ||
| Q1 25 | 3.6% | 48.2% | ||
| Q4 24 | 22.5% | 48.6% | ||
| Q3 24 | 15.8% | 45.8% | ||
| Q2 24 | 48.0% | 44.7% | ||
| Q1 24 | 3.4% | 52.6% |
净利率OUTUTHR
| Q4 25 | 18.9% | 46.1% | ||
| Q3 25 | 11.0% | 42.4% | ||
| Q2 25 | 4.2% | 38.8% | ||
| Q1 25 | -5.3% | 40.6% | ||
| Q4 24 | 15.0% | 40.9% | ||
| Q3 24 | 7.7% | 41.3% | ||
| Q2 24 | 37.0% | 38.9% | ||
| Q1 24 | -6.7% | 45.2% |
每股收益（稀释后）OUTUTHR
| Q4 25 | $0.57 | $7.66 | ||
| Q3 25 | $0.29 | $7.16 | ||
| Q2 25 | $0.10 | $6.41 | ||
| Q1 25 | $-0.14 | $6.63 | ||
| Q4 24 | $0.49 | $6.23 | ||
| Q3 24 | $0.19 | $6.39 | ||
| Q2 24 | $1.01 | $5.85 | ||
| Q1 24 | $-0.18 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $99.9M | $2.9B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $710.4M | $7.1B |
| 总资产 | $5.3B | $7.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OUTUTHR
| Q4 25 | $99.9M | $2.9B | ||
| Q3 25 | $63.0M | $2.8B | ||
| Q2 25 | $28.5M | $3.0B | ||
| Q1 25 | $30.5M | $3.3B | ||
| Q4 24 | $46.9M | $3.3B | ||
| Q3 24 | $28.0M | $3.3B | ||
| Q2 24 | $49.6M | $3.0B | ||
| Q1 24 | $42.4M | $2.7B |
股东权益OUTUTHR
| Q4 25 | $710.4M | $7.1B | ||
| Q3 25 | $542.6M | $6.6B | ||
| Q2 25 | $539.1M | $7.2B | ||
| Q1 25 | $566.9M | $6.8B | ||
| Q4 24 | $649.0M | $6.4B | ||
| Q3 24 | $618.2M | $6.1B | ||
| Q2 24 | $664.9M | $5.7B | ||
| Q1 24 | $524.2M | $5.3B |
总资产OUTUTHR
| Q4 25 | $5.3B | $7.9B | ||
| Q3 25 | $5.2B | $7.4B | ||
| Q2 25 | $5.1B | $7.9B | ||
| Q1 25 | $5.1B | $7.7B | ||
| Q4 24 | $5.2B | $7.4B | ||
| Q3 24 | $5.2B | $7.1B | ||
| Q2 24 | $5.3B | $6.7B | ||
| Q1 24 | $5.5B | $6.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $118.1M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $93.3M | $173.3M |
| 自由现金流率自由现金流/营收 | 18.2% | 21.9% |
| 资本支出强度资本支出/营收 | 4.8% | 21.9% |
| 现金转化率经营现金流/净利润 | 1.22× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $218.8M | $1.0B |
8季度趋势，按日历期对齐
经营现金流OUTUTHR
| Q4 25 | $118.1M | $346.2M | ||
| Q3 25 | $88.8M | $562.1M | ||
| Q2 25 | $67.1M | $191.7M | ||
| Q1 25 | $33.6M | $461.2M | ||
| Q4 24 | $124.5M | $341.2M | ||
| Q3 24 | $73.1M | $377.2M | ||
| Q2 24 | $71.0M | $232.2M | ||
| Q1 24 | $30.6M | $376.5M |
自由现金流OUTUTHR
| Q4 25 | $93.3M | $173.3M | ||
| Q3 25 | $67.7M | $351.6M | ||
| Q2 25 | $41.4M | $129.5M | ||
| Q1 25 | $16.4M | $386.3M | ||
| Q4 24 | $106.3M | $254.5M | ||
| Q3 24 | $55.5M | $300.7M | ||
| Q2 24 | $47.1M | $187.1M | ||
| Q1 24 | $12.2M | $338.3M |
自由现金流率OUTUTHR
| Q4 25 | 18.2% | 21.9% | ||
| Q3 25 | 14.5% | 44.0% | ||
| Q2 25 | 9.0% | 16.2% | ||
| Q1 25 | 4.2% | 48.6% | ||
| Q4 24 | 21.6% | 34.6% | ||
| Q3 24 | 12.3% | 40.2% | ||
| Q2 24 | 9.9% | 26.2% | ||
| Q1 24 | 3.0% | 49.9% |
资本支出强度OUTUTHR
| Q4 25 | 4.8% | 21.9% | ||
| Q3 25 | 4.5% | 26.3% | ||
| Q2 25 | 5.6% | 7.8% | ||
| Q1 25 | 4.4% | 9.4% | ||
| Q4 24 | 3.7% | 11.8% | ||
| Q3 24 | 3.9% | 10.2% | ||
| Q2 24 | 5.0% | 6.3% | ||
| Q1 24 | 4.5% | 5.6% |
现金转化率OUTUTHR
| Q4 25 | 1.22× | 0.95× | ||
| Q3 25 | 1.73× | 1.66× | ||
| Q2 25 | 3.44× | 0.62× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | 1.68× | 1.13× | ||
| Q3 24 | 2.11× | 1.22× | ||
| Q2 24 | 0.40× | 0.83× | ||
| Q1 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OUT
| Static Displays | $236.3M | 46% |
| Other | $134.8M | 26% |
| Digital Displays | $125.3M | 24% |
| Other Revenues | $1.9M | 0% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
